Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
GMM Pfaudler US completes acquisition of MixPro
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
The product is expected to be launched in FY25
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Both the India and GCC entities will be operated by separate dedicated management teams
Subscribe To Our Newsletter & Stay Updated
